Jun 13, 2020
EHA25Virtual: Study of Subcutaneous Daratumumab Shows Improved Clinical Outcomes in the Treatment of Patients with Amyloidosis
Mar 05, 2020
Amyloidosis Patient Registry Hits 300 Participants and is Now Available to Entire Community
Feb 06, 2020
Cellectricon and StressMarq Biosciences collaborate to develop next generation reagents and assays to advance neurodegenerative disease research
Jan 15, 2020
Life Molecular Imaging announces presentation of new scientific data at the Human Amyloid Imaging Meeting
Nov 07, 2019
ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease
Oct 24, 2019
ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease
Oct 17, 2019
ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau
Oct 03, 2019
Excelera Network® and Pfizer Partner for Distribution of World's First Treatment for Transthyretin Amyloid Cardiomyopathy
Aug 27, 2019
ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board
Jul 10, 2019
ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference
Jul 09, 2019
Applied BioMath, LLC to Present at Alzheimer's Association International Conference®
Jul 09, 2019
ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports
Jun 27, 2019
ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
Jun 19, 2019
ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board
Jun 05, 2019
ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference
May 28, 2019
ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of Tau
May 14, 2019
oneAMYLOIDOSISvoice.com Support Group Platform Begins Empowering the Amyloidosis Community with Invaluable Info About Amyloidosis Symptoms, Diagnosis, Treatment, Survival
May 08, 2019
Optina Diagnostics Receives Breakthrough Device Designation from U.S. FDA for a Retinal Imaging Platform to Aid in the Diagnosis of Alzheimer's Disease
May 06, 2019
FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin-mediated amyloidosis
Apr 26, 2019
Life Molecular Imaging and Institut de Radiofarmàcia Aplicada de Barcelona (IRAB) Announce a Strategic Partnership for Production of NeuraCeq and PI-2620 in Barcelona